Evidence map›Paper›PMID 26231887›Full record

ArticleBMC cancer2015

Extracellular vesicle-mediated phenotype switching in malignant and non-malignant colon cells.

Hillary E Mulvey, Audrey Chang, Jason Adler, Michael Del Tatto, Kimberly Perez, Peter J Quesenberry, Devasis Chatterjee

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Extracellular Vesicles as Signal Carriers in Malignant Thyroid Tumors?International journal of molecular sciences · 2022
    Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Hillary E MulveyDepartment of Medicine, Rhode Island Hospital and The Alpert Medical School of Brown University, Coro West, Suite 5.01, One Hoppin St, Providence, RI, 02903, USA. hillary.e.mulvey@gmail.com.
Audrey ChangDepartment of Medicine, Rhode Island Hospital and The Alpert Medical School of Brown University, Coro West, Suite 5.01, One Hoppin St, Providence, RI, 02903, USA. audreyyychang@gmail.com.
Jason AdlerDepartment of Medicine, Rhode Island Hospital and The Alpert Medical School of Brown University, Coro West, Suite 5.01, One Hoppin St, Providence, RI, 02903, USA. jaadler23@gmail.com.
Michael Del TattoDepartment of Medicine, Rhode Island Hospital and The Alpert Medical School of Brown University, Coro West, Suite 5.01, One Hoppin St, Providence, RI, 02903, USA. mdeltatto1@lifespan.org.
Kimberly PerezDepartment of Medicine, Rhode Island Hospital and The Alpert Medical School of Brown University, Coro West, Suite 5.01, One Hoppin St, Providence, RI, 02903, USA. kperez@lifespan.org.
Peter J QuesenberryDepartment of Medicine, Rhode Island Hospital and The Alpert Medical School of Brown University, Coro West, Suite 5.01, One Hoppin St, Providence, RI, 02903, USA. pquesenberry@lifespan.org.
Devasis ChatterjeeDepartment of Medicine, Rhode Island Hospital and The Alpert Medical School of Brown University, Coro West, Suite 5.01, One Hoppin St, Providence, RI, 02903, USA. Devasis_chatterjee@brown.edu.
Rhode Island Hospital · USBrown University · US

Funding

UCP2 expression in colon cancerP20RR017695 · NCRR · RHODE ISLAND HOSPITAL (PROVIDENCE, RI) · PI HIXSON, DOUGLAS CARTER · 2002 to 2011
$15.0M
Stem Cell Biology: New Directions in Clinical and Basic ResearchP20GM103468 · NIGMS · RHODE ISLAND HOSPITAL · PI QUESENBERRY, PETER J. · 2012 to 2013
$4.5M
COBRE Center for Cancer Research DevelopmentP20GM103421 · NIGMS · RHODE ISLAND HOSPITAL · PI RAMRATNAM, BHARAT · 2012 to 2013
$4.5M
NCRR NIH HHS P20 RR 017695NCRR NIH HHS P20 RR017695NIGMS NIH HHS P20 GM103421NIGMS NIH HHS P20GM103421NIGMS NIH HHS P20 GM103468NIGMS NIH HHS P20GM103468
6 · The paper itself

Abstract

backgroundExtracellular vesicles (EVs) are secreted from many cells, carrying cargoes including proteins and nucleic acids. Research has shown that EVs play a role in a variety of biological processes including immunity, bone formation and recently they have been implicated in promotion of a metastatic phenotype.

methodsEVs were isolated from HCT116 colon cancer cells, 1459 non-malignant colon fibroblast cells, and tumor and normal colon tissue from a patient sample. Co-cultures were performed with 1459 cells and malignant vesicles, as well as HCT116 cells and non-malignant vesicles. Malignant phenotype was measured using soft agar colony formation assay. Co-cultures were also analyzed for protein levels using mass spectrometry. The importance of 14-3-3 zeta/delta in transfer of malignant phenotype was explored using siRNA. Additionally, luciferase reporter assay was used to measure the transcriptional activity of NF-κB.

resultsThis study demonstrates the ability of EVs derived from malignant colon cancer cell line and malignant patient tissue to induce the malignant phenotype in non-malignant colon cells. Similarly, EVs derived from non-malignant colon cell lines and normal patient tissue reversed the malignant phenotype of HCT116 cells. Cells expressing an EV-induced malignant phenotype showed increased transcriptional activity of NF-κB which was inhibited by the NF--κB inhibitor, BAY117082. We also demonstrate that knock down of 14-3-3 zeta/delta reduced anchorage-independent growth of HCT116 cells and 1459 cells co-cultured with HCT derived EVs.

conclusionsEvidence of EV-mediated induction of malignant phenotype, and reversal of malignant phenotype, provides rational basis for further study of the role of EVs in tumorigenesis. Identification of 14-3-3 zeta/delta as up-regulated in malignancy suggests its potential as a putative drug target for the treatment of colorectal cancer.

Indexed as

14-3-3 ProteinsCell Line, TumorCoculture TechniquesColonColonic NeoplasmsExtracellular VesiclesFibroblastsGene Expression Regulation, NeoplasticHCT116 CellsHumansPhenotypeUp-Regulation14-3-3 ProteinsYWHAZ protein, human

Identifiers

PMID26231887
PMCPMC4522096
OpenAlexW1628962479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.